A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients

被引：0
|
作者：
Haeberle, L. [1 ]
Erber, R. [2 ]
Gass, P. [1 ]
Hein, A. [1 ]
Jud, S. M. [1 ]
Langemann, H. [1 ]
Rauh, C. [1 ]
Hack, C. C. [1 ]
Schulz-Wendtland, R. [3 ]
Hartmann, A. [2 ]
Beckmann, M. W. [1 ]
Lux, M. P. [1 ]
Fasching, P. A. [1 ]
机构：
[1] Erlangen Univ Hosp, Dept Gynecol & Obstet, Erlangen, Germany
[2] Erlangen Univ Hosp, Inst Pathol, Erlangen, Germany
[3] Erlangen Univ Hosp, Inst Radiol, Erlangen, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
226P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prediction of pathological complete response to neoadjuvant chemotherapy in early triple negative breast cancer patients by serial breast ultrasound examination
    Rapoport, Bernardo
    Smit, Teresa
    Heyman, Liezl
    Moosa, Farhana
    Benn, Carol Ann
    CANCER RESEARCH, 2021, 81 (04)
  • [22] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06): : 1673 - 1681
  • [23] MRI in diagnosis of pathological complete response in breast cancer patients after neoadjuvant chemotherapy
    Li, Yan-Ling
    Zhang, Xiao-Peng
    Li, Jie
    Cao, Kun
    Cui, Yong
    Li, Xiao-Ting
    Sun, Ying-Shi
    EUROPEAN JOURNAL OF RADIOLOGY, 2015, 84 (02) : 242 - 249
  • [24] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 63 - 68
  • [25] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [26] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
  • [27] Impact of tumor size on prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer
    Singh, R.
    Kumar, S.
    Gogia, A.
    Sharma, D.
    Deo, S.
    BREAST, 2019, 44 : S70 - S71
  • [28] Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
    Montemurro, Filippo
    Di Cosimo, Serena
    BREAST, 2014, 23 (05): : 690 - 691
  • [29] Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients
    Michishita, Shintaro
    Kim, Seung Jin
    Shimazu, Kenzo
    Sota, Yoshiaki
    Naoi, Yasuto
    Maruyama, Naomi
    Kagara, Naofumi
    Shimoda, Masafumi
    Shimomura, Atsushi
    Noguchi, Shinzaburo
    BREAST, 2015, 24 (02): : 159 - 165
  • [30] Development of a predictive model by gene expression profiles for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
    Fujiki, Y.
    Yamamoto, Y.
    Yamamoto-Ibusuki, M.
    Goto, R.
    Tomiguchi, M.
    Sueta, A.
    Takeshita, T.
    Iwase, H.
    CANCER RESEARCH, 2017, 77
12345